Meeting
2015 Gastrointestinal Cancers Symposium
FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC).
Authors
Albert C. Lockhart
Washington University in St. Louis, St. Louis, MO
Albert C. Lockhart , Kenneth Anthony Krajewski , Andrea Wang-Gillam , Manik Amin , Steven Sorscher , Kian-Huat Lim , Benjamin R. Tan Jr., Joel Picus , Anne Hecky , Kenisha Allen , Jaclyn D Peterson , Emily O'Day , Robert de Wilton Marsh , Mark Kozloff , Blase N. Polite , Hedy Lee Kindler , Manish Sharma , Daniel Virgil Thomas Catenacci
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
01928290
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 177)
DOI
10.1200/jco.2015.33.3_suppl.177
Abstract #
177
Poster Bd #
D25
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.
First Author: Ramon Jin
Poster
2018 Gastrointestinal Cancers Symposium
A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma.
First Author: Haeseong Park
Poster
2018 ASCO Quality Care Symposium
Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
First Author: Robert Kudlovich
Poster
2022 ASCO Annual Meeting
Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018).
First Author: Angela Damato